EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Research output: Book/ReportReportResearchpeer-review

Standard

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. / Publication, EFSA; Tetens, Inge.

European Food Safety Authority, 2011.

Research output: Book/ReportReportResearchpeer-review

Harvard

Publication, EFSA & Tetens, I 2011, EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. European Food Safety Authority. https://doi.org/10.2903/j.efsa.2011.2472

APA

Publication, EFSA., & Tetens, I. (2011). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. European Food Safety Authority. https://doi.org/10.2903/j.efsa.2011.2472

Vancouver

Publication EFSA, Tetens I. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. European Food Safety Authority, 2011. https://doi.org/10.2903/j.efsa.2011.2472

Author

Publication, EFSA ; Tetens, Inge. / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. European Food Safety Authority, 2011.

Bibtex

@book{f3ca87b56f764ca286714e22e8191d0a,
title = "EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno{\textregistered} GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006",
abstract = "Following an application from Clasado Ltd., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to Bimuno{\textregistered} GOS and reducing gastro-intestinal discomfort. The food constituent that is the subject of the health claim, Bimuno{\textregistered} GOS, is sufficiently characterised. The claimed effect is reduction of gastro-intestinal discomfort, which is a beneficial physiological effect. The applicant identified eight human intervention studies, two human observational studies, and three non-human studies as being pertinent to the health claim. The Panel considers that owing to important methodological limitations, no conclusions with respect to the scientific substantiation of the claim can be drawn from the two human intervention studies which investigated the effect of Bimuno{\textregistered} GOS on symptoms related to gastro-intestinal discomfort. The remaining human studies, and the animal and in vitro studies, addressed the effects of either Bimuno{\textregistered} GOS or other galacto-oligosaccharides from a variety of sources on the gut microbiota. The Panel considers that the evidence provided does not establish that an effect of Bimuno{\textregistered} GOS on bifidobacteria per se is sufficient to predict an effect of Bimuno{\textregistered} GOS on gastro-intestinal discomfort in vivo in humans. The Panel considers that no human studies have been provided from which conclusions can be drawn for the scientific substantiation of the claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of Bimuno{\textregistered} GOS and reducing gastro-intestinal discomfort. {\textcopyright} European Food Safety Authority, 2011",
author = "EFSA Publication and Inge Tetens",
year = "2011",
doi = "10.2903/j.efsa.2011.2472",
language = "English",
publisher = "European Food Safety Authority",

}

RIS

TY - RPRT

T1 - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006

AU - Publication, EFSA

AU - Tetens, Inge

PY - 2011

Y1 - 2011

N2 - Following an application from Clasado Ltd., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort. The food constituent that is the subject of the health claim, Bimuno® GOS, is sufficiently characterised. The claimed effect is reduction of gastro-intestinal discomfort, which is a beneficial physiological effect. The applicant identified eight human intervention studies, two human observational studies, and three non-human studies as being pertinent to the health claim. The Panel considers that owing to important methodological limitations, no conclusions with respect to the scientific substantiation of the claim can be drawn from the two human intervention studies which investigated the effect of Bimuno® GOS on symptoms related to gastro-intestinal discomfort. The remaining human studies, and the animal and in vitro studies, addressed the effects of either Bimuno® GOS or other galacto-oligosaccharides from a variety of sources on the gut microbiota. The Panel considers that the evidence provided does not establish that an effect of Bimuno® GOS on bifidobacteria per se is sufficient to predict an effect of Bimuno® GOS on gastro-intestinal discomfort in vivo in humans. The Panel considers that no human studies have been provided from which conclusions can be drawn for the scientific substantiation of the claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of Bimuno® GOS and reducing gastro-intestinal discomfort. © European Food Safety Authority, 2011

AB - Following an application from Clasado Ltd., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort. The food constituent that is the subject of the health claim, Bimuno® GOS, is sufficiently characterised. The claimed effect is reduction of gastro-intestinal discomfort, which is a beneficial physiological effect. The applicant identified eight human intervention studies, two human observational studies, and three non-human studies as being pertinent to the health claim. The Panel considers that owing to important methodological limitations, no conclusions with respect to the scientific substantiation of the claim can be drawn from the two human intervention studies which investigated the effect of Bimuno® GOS on symptoms related to gastro-intestinal discomfort. The remaining human studies, and the animal and in vitro studies, addressed the effects of either Bimuno® GOS or other galacto-oligosaccharides from a variety of sources on the gut microbiota. The Panel considers that the evidence provided does not establish that an effect of Bimuno® GOS on bifidobacteria per se is sufficient to predict an effect of Bimuno® GOS on gastro-intestinal discomfort in vivo in humans. The Panel considers that no human studies have been provided from which conclusions can be drawn for the scientific substantiation of the claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of Bimuno® GOS and reducing gastro-intestinal discomfort. © European Food Safety Authority, 2011

U2 - 10.2903/j.efsa.2011.2472

DO - 10.2903/j.efsa.2011.2472

M3 - Report

BT - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006

PB - European Food Safety Authority

ER -

ID: 208962898